Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid.
Treatment of operable breast cancer patients with a single injection of 60 mg poly(A); poly(U) (polyadenylic, polyuridylic acid) resulted in an enhancement of natural killer (NK) cell cytotoxicity against human myeloid K562 target cells. Furthermore, the level of 2-5A synthetase in peripheral blood lymphocytes of such patients was increased after the treatment. Both of these effects, measured 24 and 48 hours after the injection of poly(A); poly(U), were statistically significant compared to their respective levels before the treatment. These events, therefore, may be used as markers to monitor the immediate response of patients toward treatment with this synthetic double-stranded RNA.
Hovanessian
A G
AG
Youn
J K
JK
Buffet-Janvresse
C
C
Riviere
Y
Y
Michelson
M
M
Lacour
J
J
Lacour
F
F
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000328:Adult; D000368:Aged; D000920:Antibody-Dependent Cell Cytotoxicity; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007372:Interferons / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology*; D008214:Lymphocytes / Q000201:enzymology; D008408:Mastectomy; D008875:Middle Aged; D011063:Poly A-U / Q000627:therapeutic use*
D011063:Poly A-U; D007372:Interferons; D015088:2',5'-Oligoadenylate Synthetase